Gland Pharma Ltd - 543245 - Board Meeting Intimation for The Approval Of Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended 30Th September 2023
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2023 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30th September 2023 Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Directorate
Reappointment of Independent Director of the Company Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 1,100 Equity Shares under ESOP 
Gland Pharma shares recover after EIR from USFDA for Hyderabad facility
This was a Pre-Approval Inspection (PAI) 7 products and Good Manufacturing Practice (GMP). Gland Pharma Ltd - 543245 - Conclusion Of US FDA Inspection At Pashamylaram Facility Of The Company
Conclusion of US FDA Inspection at Pashamylaram Facility of the Company Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of the Investor Meeting Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of the Investor Meeting Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of the Investor Meetings Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Management
Appointment of Chief Executive Officer (President) for Phixen S.A.S. (Cenexi); the wholly-owned step-down subsidiary of Gland Pharma Limited